This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Delving into the topline data from the Phase 2 clinical trial of NBI-1117568 in adults with schizophrenia
Ticker(s): NBIXWho's the expert?
Institution: Self-employed
- Psychiatrist in practice for 18 years
- treats 10 patients with schizophrenia
Interview Goalto discuss the current treatment landscape and the potential of NBI-1117568, an M4 selective orthosteric agonist being developed by Neurocrine for the treatment of schizophrenia.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
